Bitar Lynn, Zouein Joseph, Haddad Fady Gh, Eid Roland, Kourie Hampig R
Department of Hematology & Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Biomark Med. 2021 Feb;15(2):135-138. doi: 10.2217/bmm-2020-0491. Epub 2021 Jan 14.
Metastatic colorectal cancer is the second most common cause of cancer death. Standard chemotherapy in combination with targeted therapies represent the backbone for the treatment of advanced disease. However, options are limited for patients progressing on these regimens. Genetic testing can offer patients the opportunity to benefit from novel therapies, namely immune checkpoint inhibitors in microsatellite instability-positive tumors. HER2 overexpression has recently emerged as a potentially targetable tumor marker in colorectal cancer (CRC). Despite the absence of approvals for anti-HER2 therapies in CRC, many agents such as trastuzumab and pertuzumab were tested and demonstrated significant antitumor activity, even in heavily pretreated patients. Early trials are also evaluating lapatinib, T-DM1, tucatinib and other anti-HER2 agents in patients with metastatic CRC, with promising results.
转移性结直肠癌是癌症死亡的第二大常见原因。标准化疗联合靶向治疗是晚期疾病治疗的主要手段。然而，对于在这些治疗方案上病情进展的患者，选择有限。基因检测可为患者提供从新型疗法中获益的机会，即微卫星不稳定阳性肿瘤中的免疫检查点抑制剂。HER2过表达最近已成为结直肠癌（CRC）中一种潜在的可靶向肿瘤标志物。尽管抗HER2疗法在CRC中尚未获批，但许多药物如曲妥珠单抗和帕妥珠单抗已进行了测试，并显示出显著的抗肿瘤活性，即使是在经过大量预处理的患者中。早期试验也在评估拉帕替尼、T-DM1、图卡替尼和其他抗HER2药物在转移性CRC患者中的疗效，结果令人鼓舞。
